630 related articles for article (PubMed ID: 17008936)
1. Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
Ahmed I; Goldstein BJ
Mt Sinai J Med; 2006 Sep; 73(5):759-68. PubMed ID: 17008936
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
Zarich SW
Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
[TBL] [Abstract][Full Text] [Related]
3. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
Kendall DM; Harmel AP
Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
[TBL] [Abstract][Full Text] [Related]
4. Lifestyle modification and endothelial function in obese subjects.
Hamdy O
Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):231-41. PubMed ID: 15853597
[TBL] [Abstract][Full Text] [Related]
5. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
Cannon CP
Am J Cardiol; 2008 Dec; 102(12A):5L-9L. PubMed ID: 19084083
[TBL] [Abstract][Full Text] [Related]
6. From hyperglycemia to the risk of cardiovascular disease.
Leiter LA
Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
[TBL] [Abstract][Full Text] [Related]
7. Association of hyperglycemia and insulin with diabetic cardiovascular complications.
Khamaisi M; Wainstein J; Hancu N; Milicevic Z; Raz I
Isr Med Assoc J; 2003 Feb; 5(2):116-9. PubMed ID: 12674662
[TBL] [Abstract][Full Text] [Related]
8. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
Chapman MJ; Sposito AC
Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
[TBL] [Abstract][Full Text] [Related]
9. Understanding type 2 diabetes mellitus and associated cardiovascular disease: linked by insulin resistance.
Tennyson GE
Am J Manag Care; 2002 Oct; 8(16 Suppl):S450-9. PubMed ID: 12408408
[TBL] [Abstract][Full Text] [Related]
10. Macrovascular complications of metabolic syndrome: an early intervention is imperative.
Tenenbaum A; Motro M; Schwammenthal E; Fisman EZ
Int J Cardiol; 2004 Nov; 97(2):167-72. PubMed ID: 15458679
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome.
Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
Rosenberg DE; Jabbour SA; Goldstein BJ
Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
Grundy SM
J Am Coll Cardiol; 2006 Mar; 47(6):1093-100. PubMed ID: 16545636
[TBL] [Abstract][Full Text] [Related]
14. New insights into understanding cardiometabolic risk. Introduction.
Fonarow GC; Watson KE
Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
[No Abstract] [Full Text] [Related]
15. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Lee M; Aronne LJ
Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular disease, metabolic syndrome and erectile dysfunction.
Müller A; Mulhall JP
Curr Opin Urol; 2006 Nov; 16(6):435-43. PubMed ID: 17053524
[TBL] [Abstract][Full Text] [Related]
17. The relation of insulin resistance syndromes to risk of cardiovascular disease.
Nesto RW
Rev Cardiovasc Med; 2003; 4 Suppl 6():S11-8. PubMed ID: 14668699
[TBL] [Abstract][Full Text] [Related]
18. Glucose, insulin, diabetes and mechanisms of arterial dysfunction.
Cameron JD; Cruickshank JK
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):677-82. PubMed ID: 17581229
[TBL] [Abstract][Full Text] [Related]
19. Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus.
Gotto AM
Am J Cardiol; 2007 Feb; 99(4A):3B-5B. PubMed ID: 17307053
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
Nesto R
Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
